# A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia

Source: https://onco.cc/trials/nct05963074/  
OnCo record `nct05963074` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Ibrutinib and Venetoclax in chronic lymphocytic leukaemia, run by Janssen Research & Development, LLC, active and no longer recruiting.

## Summary

A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia is a phase 2 interventional study registered as NCT05963074 by Janssen Research & Development, LLC, with 333 participants enrolled, started 2024-05-30 and due to reach its primary completion in 2027-12-15. Interventions recorded: Ibrutinib and Venetoclax.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05963074
- Phase: 2
- Setting: Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients With Previously Untreated Chronic Lymphocytic Leukemia
- Sponsor: Janssen Research & Development, LLC
- Enrolled: 333

## Sources

- ClinicalTrials.gov NCT05963074: https://clinicaltrials.gov/study/NCT05963074

## Connected records

- cancers: [Chronic lymphocytic leukaemia](https://onco.cc/cancers/cll/)
- drugs: [Ibrutinib](https://onco.cc/drugs/ibrutinib/), [Venetoclax](https://onco.cc/drugs/venetoclax/)
- companies: [AbbVie (incl. ImmunoGen, Capstan)](https://onco.cc/companies/abbvie/), [Johnson & Johnson](https://onco.cc/companies/johnson-johnson/)

---
JSON: https://onco.cc/api/v1/entities/nct05963074.json